Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Prothena Corporation PLC    PRTA   IE00B91XRN20

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
55.12(c) 54.81(c) 51.93(c) 44.6(c) 45.97(c) Last
211 748 405 504 438 591 1 242 380 748 606 Volume
-1.80% -0.56% -5.25% -14.12% +3.07% Change
More quotes
Financials ($)
Sales 2017 27,5 M
EBIT 2017 -164 M
Net income 2017 -164 M
Finance 2017 399 M
Yield 2017 -
Sales 2018 14,3 M
EBIT 2018 -218 M
Net income 2018 -218 M
Finance 2018 278 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 49,5x
EV / Sales2018 104x
Capitalization 1 760 M
More Financials
Company
Prothena Corp. Plc is a clinical stage biotechnology company, which engages in the discovery, development, and commercialization of novel antibodies.Its antibody-based product candidates target a number of potential indications including AL amyloidosis, Parkinson's disease and related... 
More about the company
Surperformance© ratings of Prothena Corporation PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTHENA CORPORATION PLC
11/16 PROTHENA : Highlights Breadth of Novel Pipeline at R&D Day
11/08 Short seller Kerrisdale targets Woodford-backed Prothena
11/07 PROTHENA : Reports Third Quarter 2017 Financial Results and Provides R&D Update
11/01 PROTHENA : to Participate in the Credit Suisse 26th Annual Healthcare Conference
10/31 PROTHENA : to Report Third Quarter 2017 Financial Results on November 7
09/28 PROTHENA : Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003..
09/18 Prothena Presents New Research Supporting Clinical Relevance of Cardiac Bioma..
09/18 PROTHENA : Presents New Research Supporting Clinical Relevance of Cardiac Biomar..
08/15 PROTHENA : to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloido..
08/15 Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloid..
More news
Sector news : Bio Therapeutic Drugs
09:50a U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/20 Midday Gainers / Losers
11/20 Premarket analyst action - healthcare
11/17 Prothena (PRTA) On R&D Day - Slideshow
11/08 Prothena slumps 8% post-earnings; Kerrisdale Capital targets
11/07 Prothena beats by $0.02, misses on revenue
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation PLC Technical Analysis Chart | PRTA | IE00B91XRN20 | 4-Traders
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 76,4 $
Spread / Average Target 66%
EPS Revisions
Managers
NameTitle
Gene G. Kinney President, Chief Executive Officer & Director
Lars G. Ekman Chairman
Tran B. Nguyen Chief Financial Officer
Sarah Noonberg Chief Medical Officer
Wagner Zago Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROTHENA CORPORATION PLC5.57%1 760
GILEAD SCIENCES1.16%94 693
REGENERON PHARMACEUTICALS6.67%41 304
VERTEX PHARMACEUTICALS100.10%36 699
GENMAB4.43%11 899
EXELIXIS, INC.76.93%7 707